Competing interests: CB received honoraria from Alimera Sciences, Apellis, Bayer, and Roche; and has served on advisory boards for Apellis, Bayer, Boehringer Ingelheim, Janssen, and Roche. CL receives honoraria from Apellis, Bayer, Biogen, and Novartis. MRM is a consultant for AbbVie, Alcon, Alimera, Allergan, Amgen, Apellis Pharmaceuticals, Astellas, Aviceda Therapeutics, Bayer, Boehringer Ingelheim, Dandelione, Eyegnos Consulting, EyePoint Pharmaceuticals, Evolve Medical Education, GenSight Biologics, Isarna Therapeutics, Iveric Bio, Kubota, LumiThera, Novartis, Oculis, OD-OS, ONL Therapeutics, OcuTerra Therapeutics, RetinAI, Roche, UBS analytics, and Zeiss. PL is a consultant for Aerie Pharmaceuticals, Allergan, Annexon, Apellis, Bausch + Lomb, Bayer, Biogen, Boehringer Ingelheim, Eyepoint, Genentech, I-Care, Novartis, Ocular Therapeutix, Outlook Therapeutics, and Roche. HO is a consultant for AbbVie, Bayer, Novartis, and Roche. TM is an employee of Bayer AG. HA, XZ, PMW and ZH are employees of Bayer Consumer Care AG. VC receives consulting fees from EyePoint Pharmaceuticals; receives grants from Bayer, Novartis, and Roche; and serves on advisory boards for Apellis, Bayer, Boehringer Ingelheim, EyePoint Pharmaceuticals, Novartis, and Roche. VC is also a member of the Eye editorial board.